A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease (Generation)

What is the purpose of this trial?

Visit the Alzheimer's Disease Research Unit (ADRU) here.

The purpose of this study is to test whether two investigational drugs called CAD106 and CNP520, administered separately, can slow down the onset and progression of clinical symptoms associated with Alzheimer's disease (AD) in participants at the risk to develop clinical symptoms based on their age and genotype.

Participation Guidelines

Ages: 60 - 75 years

Gender: Both

Novartis Pharmaceuticals

Start Date: 08/03/2016

End Date: 08/31/2023

Last Updated: 02/22/2018

Study HIC#: 1601017111

Get Involved

For more information about this study, contact:
Emily C Kemp

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image


Christopher H Van Dyck

Principal Investigator